News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
258,961 Results
Type
Article (13827)
Company Profile (293)
Press Release (244841)
Section
Business (79301)
Career Advice (147)
Deals (13177)
Drug Delivery (31)
Drug Development (50262)
Employer Resources (31)
FDA (5668)
Job Trends (5108)
News (144018)
Policy (10013)
Tag
Academia (901)
Alliances (21438)
Alzheimer's disease (729)
Approvals (5631)
Artificial intelligence (59)
Bankruptcy (97)
Best Places to Work (4457)
Biotechnology (241)
Breast cancer (57)
Cancer (574)
Cardiovascular disease (52)
Career advice (128)
CAR-T (44)
Cell therapy (149)
Clinical research (39582)
Collaboration (202)
Compensation (83)
COVID-19 (998)
C-suite (53)
Cystic fibrosis (61)
Data (612)
Diabetes (64)
Diagnostics (1191)
Earnings (28581)
Events (46508)
Executive appointments (154)
FDA (5911)
Funding (207)
Gene editing (48)
Gene therapy (127)
GLP-1 (290)
Government (1063)
Healthcare (6527)
Infectious disease (1027)
Inflammatory bowel disease (89)
IPO (7168)
Job creations (859)
Job search strategy (124)
Layoffs (181)
Legal (1372)
Lung cancer (101)
Manufacturing (66)
Medical device (2548)
Medtech (2549)
Mergers & acquisitions (6088)
Metabolic disorders (203)
Neuroscience (909)
NextGen Class of 2024 (1996)
Non-profit (841)
Northern California (783)
Obesity (117)
Opinion (90)
Parkinson's disease (55)
Patents (45)
People (24888)
Pharmaceutical (48)
Phase I (13911)
Phase II (18405)
Phase III (11681)
Pipeline (139)
Postmarket research (846)
Preclinical (5872)
Radiopharmaceuticals (203)
Rare diseases (140)
Real estate (1409)
Regulatory (8159)
Research institute (930)
Southern California (725)
Startups (1963)
United States (6586)
Vaccines (153)
Weight loss (74)
Date
Today (146)
Last 7 days (517)
Last 30 days (1828)
Last 365 days (20676)
2024 (17687)
2023 (22412)
2022 (26823)
2021 (27807)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13746)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16764)
Australia (2819)
California (1777)
Canada (645)
China (134)
Colorado (65)
Connecticut (71)
Europe (36077)
Florida (191)
Georgia (51)
Illinois (111)
Indiana (51)
Kansas (54)
Maryland (261)
Massachusetts (1479)
Michigan (45)
Minnesota (82)
New Jersey (482)
New York (541)
North Carolina (381)
Northern California (783)
Ohio (72)
Pennsylvania (374)
South America (207)
Southern California (725)
Texas (181)
Washington State (197)
258,961 Results for "entasis therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Innoviva to Acquire Entasis Therapeutics
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), and Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”), today announced the companies have entered into a definitive merger agreement under which Innoviva is to acquire all of the outstanding shares of Entasis not already owned by Innoviva at a price of $2.20 per share in cash.
May 23, 2022
·
10 min read
Deals
Innoviva Completes Acquisition of Entasis Therapeutics
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties, today announced the successful completion of its acquisition of Entasis Therapeutics Holdings Inc.
July 11, 2022
·
5 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Deals
Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc.
July 8, 2022
·
5 min read
Drug Development
Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022
Entasis Therapeutics Holdings Inc. , a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, and wholly owned subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced the presentation of additional safety and efficacy data from the Company’s pivotal Phase 3 ATTACK trial.
October 19, 2022
·
9 min read
Business
Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business Update
Entasis Therapeutics Holdings Inc. today announced its first quarter 2022 financial results and provided a business update.
April 27, 2022
·
9 min read
Business
Innoviva Snaps Up Remaining Entasis Shares, High Potential Assets
Burlingame, CA-based Innoviva is buying all of Waltham, MA-based Entasis Therapeutics’ available shares at $2.20 per share. Currently, Innoviva owns about 60% of Entasis’ outstanding shares.
May 23, 2022
·
3 min read
·
Mark Terry
Business
Entasis Therapeutics Announces Year End 2021 Financial Results and Provides Business Update
Entasis Therapeutics Holdings Inc. today announced full year 2021 financial results and provided a business update.
March 3, 2022
·
10 min read
Deals
Entasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc.
Entasis Therapeutics Holdings Inc. today announced that its Board of Directors received a preliminary, non-binding proposal from its majority stockholder Innoviva, Inc. (“Innoviva”) to acquire all of the outstanding equity securities of Entasis that are not currently owned by Innoviva for a per share consideration of $1.80 payable in cash.
February 2, 2022
·
3 min read
Genetown
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022Six abstracts selected for presentation, including three oral presentations
Entasis Therapeutics Holdings Inc. announced that six abstracts highlighting sulbactam-durlobactam have been selected for presentation at IDWeek 2022, the annual meeting of the Infectious Disease Society of America taking place October 19-23, 2022 in Washington, D.C.
October 12, 2022
·
6 min read
1 of 25,897
Next